Humacyte (HUMA) Competitors $2.33 -0.09 (-3.72%) Closing price 04:00 PM EasternExtended Trading$2.39 +0.06 (+2.58%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HUMA vs. EWTX, TVTX, CVAC, PAHC, ABCL, CALT, HROW, WVE, AMPH, and GPCRShould you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Edgewise Therapeutics (EWTX), Travere Therapeutics (TVTX), CureVac (CVAC), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Calliditas Therapeutics AB (publ) (CALT), Harrow (HROW), WAVE Life Sciences (WVE), Amphastar Pharmaceuticals (AMPH), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry. Humacyte vs. Its Competitors Edgewise Therapeutics Travere Therapeutics CureVac Phibro Animal Health AbCellera Biologics Calliditas Therapeutics AB (publ) Harrow WAVE Life Sciences Amphastar Pharmaceuticals Structure Therapeutics Humacyte (NASDAQ:HUMA) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk. Which has higher earnings and valuation, HUMA or EWTX? Edgewise Therapeutics has lower revenue, but higher earnings than Humacyte. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHumacyte$1.57M230.21-$148.70M-$0.69-3.38Edgewise TherapeuticsN/AN/A-$133.81M-$1.55-8.74 Does the media prefer HUMA or EWTX? In the previous week, Edgewise Therapeutics had 3 more articles in the media than Humacyte. MarketBeat recorded 4 mentions for Edgewise Therapeutics and 1 mentions for Humacyte. Humacyte's average media sentiment score of 0.49 beat Edgewise Therapeutics' score of 0.47 indicating that Humacyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, HUMA or EWTX? Humacyte has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Do analysts rate HUMA or EWTX? Humacyte currently has a consensus price target of $11.71, indicating a potential upside of 402.76%. Edgewise Therapeutics has a consensus price target of $40.00, indicating a potential upside of 195.42%. Given Humacyte's stronger consensus rating and higher possible upside, equities research analysts clearly believe Humacyte is more favorable than Edgewise Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80 Do insiders and institutionals believe in HUMA or EWTX? 44.7% of Humacyte shares are owned by institutional investors. 5.1% of Humacyte shares are owned by insiders. Comparatively, 23.2% of Edgewise Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is HUMA or EWTX more profitable? Humacyte's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets HumacyteN/A N/A -73.59% Edgewise Therapeutics N/A -30.95%-29.45% SummaryHumacyte beats Edgewise Therapeutics on 9 of the 14 factors compared between the two stocks. Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HUMA vs. The Competition Export to ExcelMetricHumacyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$375.39M$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E RatioN/A8.2821.0120.09Price / Sales230.21303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book-5.687.678.125.65Net Income-$148.70M-$55.28M$3.25B$257.91M7 Day Performance0.87%2.50%0.97%2.09%1 Month Performance-1.27%11.70%7.36%11.13%1 Year Performance-69.88%4.89%31.31%18.40% Humacyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HUMAHumacyte1.5776 of 5 stars$2.33-3.7%$11.71+402.8%-70.4%$375.39M$1.57M0.00150EWTXEdgewise Therapeutics1.4953 of 5 stars$12.61-3.2%$40.00+217.2%-36.1%$1.33BN/A-8.1460TVTXTravere Therapeutics3.7272 of 5 stars$14.60-2.7%$32.14+120.2%+60.4%$1.30B$273.53M-5.20460News CoverageAnalyst RevisionCVACCureVac4.7525 of 5 stars$5.41-0.7%$6.83+26.3%+47.9%$1.21B$523.70M5.88880Positive NewsPAHCPhibro Animal Health4.0498 of 5 stars$29.90+6.8%$24.40-18.4%+56.3%$1.21B$1.02B38.331,940News CoverageHigh Trading VolumeABCLAbCellera Biologics2.3189 of 5 stars$4.03+6.1%$7.50+86.1%+15.7%$1.20B$28.83M-7.20500High Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180HROWHarrow2.3814 of 5 stars$31.36-1.2%$61.40+95.8%+43.7%$1.15B$199.61M-56.00180Trending NewsAnalyst RevisionWVEWAVE Life Sciences4.5817 of 5 stars$7.06+1.6%$20.50+190.4%+35.5%$1.10B$108.30M-8.40240Analyst ForecastAMPHAmphastar Pharmaceuticals4.3171 of 5 stars$22.86-1.5%$32.33+41.4%-45.0%$1.08B$731.97M8.282,028GPCRStructure Therapeutics2.9436 of 5 stars$18.73-8.0%$76.17+306.7%-49.1%$1.07BN/A-21.53136 Related Companies and Tools Related Companies EWTX Competitors TVTX Competitors CVAC Competitors PAHC Competitors ABCL Competitors CALT Competitors HROW Competitors WVE Competitors AMPH Competitors GPCR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HUMA) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
